International Wound Journal Publishes Positive Phase 2 Interim Data on Cell-free Amniotic Fluid Injectable Biologic for the Treatment of Venous Leg Ulcers
Key Findings:
Wound Duration Prior to Treatment: Prior to injection therapy, the patients' VLUs persisted for a median duration of 7 months despite correcting the underlying venous reflux and standard-of-care interventions.
Pain Reduction: Mean pain scores were significantly reduced by the study end.
Total Wound Closure: 66.7% of patients achieved complete wound closure by the one-month post-trial follow-up.
Wound Area Reduction: The average percent reduction of ulcer area was 83.7% in patients that completed the 12-week treatment duration.
Long-Term Chronic Wounds Treated: The average duration of ulcers before study enrollment was 73 weeks, emphasizing the challenge of treating these cases with standard care alone.
'These results are highly encouraging, particularly given the long-standing, non-healing nature of the wounds treated in this study and support the growing body of evidence demonstrating efficacy and safety of this novel subcutaneous biologic for chronic venous leg ulcers,' said Chris Broderick, Merakris' CEO. 'MTX-001 represents an innovative therapeutic approach to significantly improving outcomes for patients suffering from chronic, recalcitrant venous leg ulcers, and if approved, could be a cost-effective therapy.'
Addressing a Critical Unmet Need in Venous Wound Care
Chronic venous insufficiency (CVI) affects millions of Americans, with up to 3% of adults in the United States developing severe venous leg ulcers (VLUs). While 60% of VLUs typically heal within 12 weeks, recurrence rates remain alarmingly high — 30% within one year and up to 70% within two years.
Advancing Innovation in Wound Healing
The primary objectives of the first part of this ongoing Phase 2 trial were to evaluate the safety and tolerability of MTX-001 while gaining insights into dosing frequency and efficacy metrics such as:
Complete wound closure
Reduction of wound size
Pain relief (VAS score)
Improved quality of life (HR-QoL)
'To our knowledge, this is the first multi-patient clinical trial evaluating cfAF therapy for chronic, non-healing VLUs,' added Chris Broderick. 'The data suggest that MTX-001 is safe, well-tolerated, and effective in patients who have undergone correction of underlying venous reflux disease. These findings support its potential role in reducing clinical burden, improving healing rates, and enhancing patient quality of life.'
Next Steps: Enrollment Open for Phase 2 Part 2
Merakris has opened patient enrollment for Part 2 of this Phase 2 clinical trial ( NCT04647240) to further assess the efficacy and safety of MTX-001.
For more information on the venous leg ulcer study or Merakris' expanded access drug program, please contact the medical affairs team at [email protected].
About Merakris Therapeutics
Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies.
Merakris Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA.
PR Contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Geographic
21 minutes ago
- National Geographic
Forget about 10,000 steps a day—science now has a more accurate number
Walking more is associated with reduced risk for dementia, diabetes, heart disease, and more—but a new study says you can get fewer than 10,000 steps a day and still see all those benefits. An explorer walks across sand dunes on Socotra, Yemen, 2018. Getting 10,000 steps in every day can be challenging, and a new study suggests 7,000 steps can reduce the risk of developing common but serious health conditions. Photograph by Martin Edstrom, Nat Geo Image Collection If you've been told that walking 10,000 steps a day is mandatory for good health, you might be surprised to learn that scientists suspect the figure was created to market pedometers and wasn't based on actual data. The number of steps that stave off numerous chronic conditions is actually much lower, according to a paper published today in Lancet Public Health that reviewed the past decade's research on steps and health. Walking just 7,000 steps a day lowers the risk of developing more than a half dozen medical conditions as well as premature death, according to the researchers. The scientists, from Australia, the United Kingdom, and Norway, analyzed dozens of studies involving 160,000 adults putting one foot in front of the other. Compared to people walking 2,000 steps, the 7,000-step total was associated with a 38 percent lower risk of dementia, a 25 percent reduction in cardiovascular disease, and 28 percent fewer falls. Mortality dropped nearly half in the 7,000-step walkers. Risks for depression and type 2 diabetes also fell, although by less than for the other conditions. It's long been known that physical activity, including moderate-intensity walking, benefits health. But this is the first time researchers were able to correlate step goals with the wide range of preventive health outcomes. 'Step counting devices are becoming so widely available that the general public wants to know what they should aim for,' says Melody Ding, a public health researcher at the University of Syndey in Australia and the study's lead author. People can now feel confident with a target of 7,000, she says. How more research led to a more accurate estimate This study 'is really exciting because it looks at how step volume makes a big difference in several major health outcomes,' says Michael Rocha, a cardiologist in Dartmouth, Massachusetts who leads walking excursions in his community as part of the nationwide Walk with a Doc health program. 'We now have more evidence to change what we are telling our patients. It doesn't have to be 10,000 a day to live longer and healthier,' he says. As recently as 2020, scientists formulating physical activity guidelines for Americans as well as for a global audience did not have enough evidence to recommend a specific step target, the study authors note. That left 10,000 steps as the public's holy grail—even as many people fell short. The large number of studies published in the past decade finally provided enough data to inform a broad step target. One study in 2023 that researchers included in their analysis, for example, found as few as 2,800 steps reduced the risk of cardiovascular disease, with the most benefits at 7,200. The reviewers did find that 10,000 steps are associated with even lower risks for a few conditions, such as cancer mortality, dementia, and depressive symptoms. But the incremental improvement above the 7,000 was small. For most other health metrics, including type 2 diabetes prevention, the extra 3,000 steps yielded no additional gains. Still, '10,000 steps may remain a viable target for people who are more active,' the study states. (Walking is great for your health. Walking backward? Even better.) Don't wait--walk The researchers reviewed results from 57 studies involving 35 groups of people. The studies involved participants from the United States, U.K., Japan, Australia, and several other countries. Some involved older adults or people who already had chronic conditions or increased risk factors, but many were conducted on healthy young adults. The majority of studies assessed deaths from all causes as well as cardiovascular disease incidence and mortality—areas where walking has long been known to offer protection. Other conditions, including cancer, type two diabetes, cognitive outcomes, mental health, and falls, were examined by a range of four to six studies. The researchers acknowledge that the small number of studies for certain conditions is a limiting factor of the review. 'Some outcomes have more data than others. As we start to accumulate more data and studies, these results may be updated in the future,' Ding says. In addition, the researchers acknowledge that walking speed likely plays a role in the health outcomes they uncovered, but they were unable to precisely determine its effect or what an ideal pace might be. Still, the confirmation that walking just 7,000 steps a day can help stave off chronic conditions, including dementia, is music to ears of many physicians. 'Aerobic exercise has consistently been shown to be one of the most robust ways to prevent and delay dementia,' says Stephanie Towns, a neuropsychologist at the Yale School of Medicine, who says mechanisms likely include increasing the flow of oxygen and nutrients to the brain as well as controlling major risk factors like hypertension. 'I personally recommend to all my patients that one of the best ways to reduce dementia risk is regularly engaging in brisk walks,' she says. Or as Ding puts it, 'definitely don't wait' for more data to accrue. Lace up your walking shoes and get active now.
UPI
an hour ago
- UPI
Mercury preservative to be removed from all flu shots, CDC says
A nurse gives an influenza virus vaccine shot to a man at a Giant Pharmacy in Fairfax, Va., on Oct. 13, 2004. File Photo by Roger L. Wollenberg/UPI | License Photo July 23 (UPI) -- The mercury-based preservative thimerosal will be removed from all flu shots distributed in the United States, Health and Human Services Director Robert F. Kennedy Jr. said Wednesday. Kennedy made the change when he signed policies from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, according to a news release Wednesday. The committee voted 5-1 with one abstention for the changes at its meeting on June 25 and 26 in Atlanta. All people, including children, who receive a single dose of influenza will have them without mercury. Kennedy, who hasn't acted on other panel recommendations from June, signed the decision instead of the leader of the CDC. Susan Monarez, who is President Donald Trump's nominee to head the agency, hasn't been confirmed by the U.S. Senate. The committee also voted 6-0 to recommend all Americans age 6 months and older to receive an annual influenza vaccine. Flu vaccines are reformulated yearly because viruses mutate and evolve. Thimerosol was added to vials of vaccine that contain more than one dose to prevent the growth of germs, including bacteria and fungi. It was removed from children's vaccines in the United States in 2001. "After more than two decades of delay, this action fulfills a long-overdue promise to protect our most vulnerable populations from unnecessary mercury exposure," Kennedy said in a statement. "Injecting any amount of mercury into children when safe, mercury-free alternatives exist defies common sense and public health responsibility. Today, we put safety first." In 1999, the U.S. Public Health Service, the American Academy of Pediatrics and vaccine manufacturers agreed that any potential risk from mercury warranted removal as soon as possible. The advisory panel didn't act until Kennedy appointed new members in June to approve the changes, which was recommended by the European Medicines Agency in 2004. The eight committee members include some vaccine skeptics and pandemic response critics. The panel heard a presentation against thimerosal from Lyn Redwood, the former leader of Children's Health Defense, an anti-vaccine group founded by Kennedy. Redwood is listed as an "expert" on the HHS employee website. In the news release, vaccine manufacturers said they have the capacity to fill vials without mercury. "With the U.S. now removing mercury from all vaccines, we urge global health authorities to follow this prudent example for the protection of children worldwide," Kennedy said. The removal affects 4% to 5% of the flu vaccine supply in the U.S., CNBC reported. Multi-doses from Sanofi's Fluzone and two shots from CSL Sequirus included thimerosal. The other flu shots were free from it, according to the CDC. "We acknowledge the recommendation of the new Advisory Committee on Immunization Practices (ACIP)," Sanofi said in a statement to The Hill. "We will have sufficient supply of Sanofi flu vaccine to support customer preference for this season." The most common side effects from thimerosal in vaccines were red and swelling at the injection site with some people allergic to it, according to the CDC. In a book by Kennedy in 2014, he wrote thimerosal was "toxic to brain tissue" and likely caused autism. A 2010 CDC study found "that prenatal and infant exposure to vaccines and immunoglobulins that contain thimerosal does not increase risk for autism spectrum disorder." In all, more than 40 studies over several decades showed no connection between thimerosol and developmental delays. Flu shots for the 2025-2026 flu season are available starting in August.
Chicago Tribune
2 hours ago
- Chicago Tribune
Oak Lawn bans kratom and THC products, though won't enforce for now
Despite the Oak Lawn Village Board voting Tuesday to prohibit the sale of kratom and THC products, Mayor Terry Vorderer says the village will wait to enforce the law. The prohibition of kratom and THC products, including Delta-9, was added to the tobacco retail regulation ordinance. But Vorderer said he learned from attorneys after the vote the ordinance may need to be reworked. 'They explained that that product is not really a tobacco product,' Vorderer said Wednesday. 'Thus, I instructed our staff not to enforce the kratom part, and we'll go back and modify or look at that.' The board tabled the measure after a June 24 meeting attendee attested to the benefits of kratom, saying he would do more research on the product. Kratom is an herbal substance from Southeast Asia commonly used for pain relief, mood enhancement and withdrawal symptoms. Though it is not regulated by the United State Food and Drug Administration, the FDA estimates about 2 million Americans used kratom in 2021. The ordinance amendment passed Tuesday stated the village was experiencing 'a proliferation of retail stores selling products containing potentially intoxicating ingredients,' including kratom and THC. 'These unregulated products result in certain adverse effects, including hallucination, vomiting, tremors, anxiety, dizziness, confusion and loss of consciousness, as well as negative impacts on certain brain functions related to memory, learning, decision making and emotions,' the ordinance states. Nearby communities have similarly worked to ban the sale of kratom and other drug products. In Tinley Park, the sale, distribution and use of kratom were made illegal last year, though businesses primarily profiting from kratom sales were given a 12-month amnesty period. The Orland Park Village Board passed a similar ordinance last May, banning kratom, tianeptine, Delta-8, and other novel synthetic and psychoactive drug products. Vorderer said he has worked to regulate the sales of drug products in Oak Lawn, saying 'we don't want to be in the drug dispensing business.' He said the Village Board previously voted not to allow marijuana dispensaries and capped the number of tobacco retailers at 12. Vorderer acknowledged he still has a lot to learn about products like kratom and their purported medical benefits and continues to discuss the affects of regulation with business owners. While for now the ban will not be enforced, village staff members will advise businesses if that changes, he said.
